Chardan Capital Initiates Coverage On Inhibikase Therapeutics with Neutral Rating, Announces Price Target of $1.5
Benzinga Newsdesk 2 weeks ago
Analyst RatingsNewsInitiationPrice Target
Chardan Capital analyst Andreas Argyrides initiates coverage on Inhibikase Therapeutics (NASDAQ:IKT) with a Neutral rating and announces Price Target of $1.5.
Chardan Capital analyst Andreas Argyrides initiates coverage on Inhibikase Therapeutics (NASDAQ:IKT) with a Neutral rating and announces Price Target of $1.5.